Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hvidovre University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
We will investigate effects of gut hormones on bone remodeling.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GLP-2 | Experimental | Glucagon-Like Peptide-2 (GLP-2) |
|
| GIP | Experimental | Glucose-dependent Insulinotropic polypeptide (GIP) |
|
| GLP-2+GIP | Experimental | GLP-2+GIP |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glucagon-Like Peptide-2 (GLP-2) | Other | Glucagon-Like Peptide-2 (GLP-2) injection. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| C-terminal telopeptide (CTX). At all time points and AUC(0-240 min). | CTX is a marker of bone resorption. Measured in serum. | -10 minutes to 600 minutes |
| N-terminal propeptide of type 1 procollagen (P1NP). At all time points and AUC(0-240 min). | P1NP is a marker of bone formation. Measured in serum. | -10 minutes to 600 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| PTH | Bone marker. Measured in serum. | -10 minutes to 600 minutes |
| Sclerostin | Bone marker. | -10 minutes to 600 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure | Measured before blood sampling. | -10 minutes to 60 minutes |
| Heart rate | Measured before blood sampling. | -10 minutes to 60 minutes |
Inclusion Criteria:
Women Age above 50 years Postmenopausal Caucasian BMI 18.5 to 28.0 kg/m2.
Exclusion Criteria:
Smoking Medication believed to influence study outcome Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb<7,0 mmol/L Decreased renal function
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hvidovre University Hospital | Hvidovre | 2650 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054795 | Incretins |
| ID | Term |
|---|---|
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Glucose-dependent insulinotropic polypeptide (GIP) |
| Other |
Glucose-dependent insulinotropic polypeptide (GIP) injection. |
|
| GLP-2+GIP | Other | GLP-2+GIP injection. |
|
| Placebo | Other | Placebo injection. |
|
| Calcium | Measured in serum within 5 days. | -10 minutes to 600 minutes |
| Glucose | Measured in serum. | -10 minutes to 600 minutes |
| Glucose-dependent insulinotropic polypeptide (GIP) | Total and intact GIP. Measured in plasma. | -10 minutes to 600 minutes |
| Insulin | Measured in serum. | -10 minutes to 600 minutes |
| C-peptide | Measured in serum. | -10 minutes to 600 minutes |
| Glukagon-like peptide-1 (GLP-1) | Measured in plasma. | -10 minutes to 600 minutes |
| Glucagon | Measured in plasma. | -10 minutes to 600 minutes |
| Glukagon-like peptide-2 (GLP-2) | Intact GLP-2. Measured in plasma. | -10 minutes to 600 minutes |
| PP | Measured in plasma. | -10 minutes to 600 minutes |
| D020164 | Chemical Actions and Uses |